Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters. The company reaffirmed its full-year compara
Abbott Laboratories (ABT) lifted its full-year earnings outlook on Thursday as the healthcare firm r
The S&P 500 Index ($SPX ) (SPY ) today is down -0.46%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.28%. September E-mini S&P futures (ESU26 ) are down -0.40%, and September E-mini Nasdaq futures...
Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.
Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The healthcare company posted adjusted earnings of $1.31 a share in the second quarter, topping Wall Street's estimate of $1.28
Abbott Laboratories stock has fallen sharply over the past year, yet both an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and traditional market multiples currently point to the shares trading at a discount. The share price is down about 30.7% over the past year, which has pushed investor sentiment lower while opening a potential valuation gap. Progress in colorectal cancer diagnostics and partnerships in continuous glucose monitoring can support long term cash...
Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 13% year on year to $12.59 billion. Its non-GAAP profit of $1.31 per share was 2.6% above analysts’ consensus estimates.
Abbott stock jumped early Thursday on better-than-expected second-quarter metrics. The company also raised its 2026 profit view.
Abbott Laboratories (NYSE:ABT) delivered stronger-than-expected second-quarter results and increased its full-year earnings guidance, sending its shares about 2. 5% higher in premarket trading.
Abbott (ABT) delivered earnings and revenue surprises of +2.34% and +0.91%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Investing.com -- Abbott (NYSE:ABT) shares are trading higher premarket on Thursday after the company reported second-quarter earnings, topping consensus expectations and raising its full-year earnings guidance.
The healthcare company said its profit fell to $928 million, or 53 cents a share, in the second quarter, from $1.78 billion, or $1.01 a share, a year earlier.
Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.
Wall Street still prices Abbott like a slow-and-steady dividend stalwart, but a pair of massive strategic moves beneath the surface suggests that framing may be costing investors a significant opportunity.
Today Earnings (a.m): UnitedHealth, GE Aerospace, U.S. Bancorp, Citizens Financial, Abbott Laboratories, State Street, Taiwan Semiconductor Manufacturing Earnings (p.m.): Netflix, Intuitive Surgical Economic data: Weekly jobless claims, Philadelphia Fed business-outlook survey, retail sales, pending home sales index, business inventories Fed speakers: Fed Vice Chair Philip Jefferson is expected to speak, as is Dallas Fed President Lorie Logan.
ABT is banking on emerging-market pharmaceutical growth and innovation in Nutrition, but macro pressures and currency swings remain key challenges.
Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.
Jorge Garces, who joined Abbott to oversee scientific strategy for cancer diagnostics after it acquired Exact Sciences, discusses the future of the field.
Johnson & Johnson raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara. The drugmaker on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated. J&J logged $25 billion in sales, in line with Wall Street estimates and up 6% from the same period last year.
Today Earnings: Johnson & Johnson, Morgan Stanley, BlackRock, PNC Financial Services, Conagra, Cintas, United Airlines, Bank of New York Mellon, Elevance Health, J.B. Hunt, ASML Economic data: Producer-price index data for June, Empire State manufacturing survey, EIA weekly petroleum status report, Fed beige book.
Intuitive Surgical stock tumbled Tuesday after HCA Healthcare trimmed its full-year earnings outlook, noting a drop in surgeries.
ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag. Here's what could shape the results.
Abbott is down nearly 23% this year while Pfizer dangles a 7% yield, and both just beat Q1 estimates. One of these discounts is a genuine buying opportunity and the other is a slow-moving trap waiting to spring.
Beyond analysts' top-and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.
Abbott Laboratories (NYSE:ABT) is one of the Best Monopoly Stocks to Buy According to Hedge Funds. On June 30, Baird initiated coverage on the company’s stock with an “Outperform” rating, setting a price objective of $121.00. The firm sees Abbott Laboratories (NYSE:ABT)’s portfolio as delivering steady top-line and earnings growth over the upcoming several years. As per […]
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
